Drug Trial Radar · NCT06414005
A Phase 2b/3 Study of TPX-115 on Partial-thickness Rotator Cuff Tear
Last checked: Nov 20, 2026Latest source record: Jun 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
166
Planned (sponsor's estimate)
Start
Apr 15, 2024
Primary completion
Jun 30, 2026
Study completion Jan 31, 2027
Sponsor
- Lead sponsor
- Tego Science, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 14, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Rotator cuff tear is one of the most common shoulder diseases and conservative treatment is commonly used for tears involving ≤50% of tendon thickness. Since conventional conservative treatments are not fundamental to repair tendon tissue, there is a growing need of new therapy to improve structural outcome. This study assesses the safety and efficacy of allogeneic fibroblasts on partial-thickness rotator cuff tear. The primary outcome is change in Constant Score (CS) at 24 weeks after TPX-115 injection. Secondary outcomes include changes from baseline in CS, Visual Analogue Score (VAS) pain score, American Shoulder and Elbow Surgeons (ASES) score, Quick Disabilities of the Arm, Shoulder and Hand (Quick-DASH), Simple Shoulder Test (SST), and functional evaluations including Range of Motion (ROM) at 4, 12, 24 and 52 weeks after administration and structural evaluation using MRI at 24 and 52 weeks after injection.
Conditions
- Partial Thickness Rotator Cuff Tear
Interventions
TPX-115Biological
Ultrasound-guided intratendinous injection of allogeneic fibroblasts (TPX-115)
Placebo (Saline)Other
Ultrasound-guided intratendinous placebo injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in shoulder score of Constant score (CS)Time frame: 24 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Seoul National University Hospital
Seoul, South Korea · Recruiting
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.